Programme at the Glance
Programme at the Glance –
Thursday 14 October 2021
08.45
09.40
Belgian Society for Thrombosis and Haemostasis
Chairs: Jan Emmerechts and Phu Quoc Le
BSTH.1.1 – 08.45 – 08.50 Introduction by the President of the BSTH
BSTH.1.2 – 08.50 – 09.15 Thrombotic antiphospholipid syndrome – Katrien Devreese, Ghent
BSTH.1.3 – 09.15 – 09.40 Inherited antithrombin deficiency revisited: novel insights in laboratory diagnosis and clinical presentation – Christelle Orlando, Brussel
09.40
10.10
Coffee Break and Poster Viewing
10.10
11.00
Belgian Society for Thrombosis and Haemostasis
Chairs: Simon De Meyer and Thomas Vanassche
BSTH.2.1 – 10.10 – 10.35 Importance of the novo lipogenesis in platelet production and function – Sandrine Horman, Louvain-la-Neuve
BSTH.2.1 – 10.35 – 11.00 Ticagrelor: a potent antiplatelet drug with unprecedented anti-staphylococcal activity – Cécile Oury, Liege
11.00
11.15
Short Break
11.15
12.00
Belgian Society for Thrombosis and Haemostasis
Chairs: Kristin Jochmans and Philip Maes
BSTH.3.1 – 11.15 – 11.30 Presentation by the winner of the Clinical/Laboratory Paul Capel prize – First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination, Severine De Bruijn, Antwerp
BSTH.3.2 – 11.30 – 11.45 Presentation by the winner of the Basic science Paul Capel prize – Neutrophils promote the progression of Staphylococcus aureus endocarditis, Severien Meyers, Leuven
Chairs: Alain Gadisseur and Kristel Vandenbosch
BSTH.3.3 – 11.45 – 12.00 Presentation by the winner of the CSL Behring encouragement award
12.00
12.40
Lunch
12.40
12.45
Opening
Frits Rosendaal, The Netherlands and Cécile Oury, Belgium
12.45
13.30
Keynote Lecture
Chairs: Cécile Oury, Belgium and Frits Rosendaal, The Netherlands
Inherited platelet disorders – Genomics, Kathleen Freson, Belgium
13.30
13.45
Short Break
13.45
14.45
Oral Communications
Chairs: Tilman Hackeng, The Netherlands and Timothée Bigot, France
OP 1.1 – 13.45 – 13.57: Selective serotonin reuptake inhibitor use is associated with major bleeding during treatment with vitamin K antagonists: results of a cohort study, Louise Burggraaf, The Netherlands
OP 1.2 – 13.57 – 14.09: Critical role of fibrin gamma-chain crosslinking by FXIIIa in preventing thrombus fragmentation and subsequent embolisation, Cédric Duval, United Kingdom
OP 1.3 – 14.09 – 14.21: Platelet-specific acetyl-CoA carboxylase 1 deletion decreases phospholipid content and impairs platelet functions, Marie Octave, Belgium
OP 1.4 – 14.21 – 14.33: TLR3 promotes venous thrombosis through endothelial cell activation, Maria Najem, France
OP 1.5 – 14.33 – 14.45: Exploring new candidate mechanisms behind antithrombin deficiency in cases with unknown molecular basis: mosaicism and intronic profiles, Pedro Garrido Rodríguez, Spain
14.45
15.30
Keynote Lecture
Chair: Pierre Morange, France
How the exposome impacts the trajectory of age related health and disease, Paul Shiels, United Kingdom
15.30
16.00
Coffee Break and Poster Viewing
16.00
17.00
Oral Communications
Chairs: Johanna Gebhart, Austria and Pierre Morange, France
OP 2.1 – 16.00 – 16.12: A hemostatic chemical compound against bleedings induced by direct oral anticoagulants., Maximilien Desvages, France
OP 2.2 – 16.12 – 16.24: Presence and evolution of NET markers and DAMPS in critically ill COVID-19 patients, Joram Huckriede, The Netherlands
OP 2.3 – 16.24 – 16.36: Global seroprevalence of pre-existing immunity against AAV serotypes in people with hemophilia A, Sebastian Wolf, Germany
OP 2.4 – 16.36 – 16.48: Hypoxia augments proinflammatory activation of endothelial cells towards a prothrombotic phenotype, Casper Ullsten-Wahlund, Norway
OP 2.5 – 16.48 – 17.00: Derivation of a predictive score for venous thromboembolism in women using combined oral contraceptives, Pierre Suchon, France
17.00
18.00
Science, Fast and Furious
Chair: Banne Nemeth, The Netherlands and Tom van de Berg, The Netherlands
SFF1.1 – 17.00 – 17.15: Correlation of calibrated automated thrombogram parameters with clinical phenotype in a large cohort of patients with antithrombin deficiency carrying different SERPINC1 variants, Carlos Bravo-Perez, Spain
SFF1.2 – 17.15 – 17.30: Inhibition of ADAMTS13 Rescues Acquired von Willebrand Syndrome in a Preclinical Left Ventricular Assist Device Animal Model, Shannen J. Deconinck, Belgium
SFF1.3 – 17.30 – 17.45: S100A8/A9 levels are increased in COVID-19 patients and induce procoagulant platelets in a GPIbα-dependent manner, Martina Colicchia, United Kingdom
SFF1.4 17.45 – 18.00: Protease Nexin-1, a serpine participating in neutrophil recruitment through CD11a integrin regulation, Célina Madjene, France
18.00
20.00
Poster Awards and Welcome Reception
08.30
09.30
Oral Communications
Chairs: Sabine Eichinger, Austria and Zsuzsa Bagoly, Hungary
OP 3.1 – 08.30 – 08.42: Genetic and clinical determinants of the outcome of immune tolerance induction in severe hemophilia A – preliminary results, Ilja Oomen, The Netherlands
OP 3.2 – 08.42 – 08.54: The Extracellular Protease EpiP from S. aureus Triggers Blood Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1, Vincenzo De Filippis, Italy
OP 3.3 – 08.54 – 09.06: Activation mechanism dependent surface exposure of cellular FXIII on platelets and platelet microparticles: immunofluorescence and immune electron microscopic study, László Muszbek, Hungary
OP 3.4 – 09.06 – 09.18: Protein S Gla domain as theranostic for early vascular calcification, Anouk Gentier, The Netherlands
OP 3.5 – 09.18 – 09.30: Remote history of venous thrombosis and the risk of venous thrombosis beyond the age of 70 years, Huijie Wang, The Netherlands
09.30
10.15
Keynote Lecture
Chair: Karen Vanhoorelbeke, Belgium
Haemophilia and gene therapy, Cedric Hermans, Belgium
10.15
10.45
Coffee Break and Poster Viewing
10.45
11.45
Oral Communications
Chairs: Anouk Gentier, The Netherlands and Christelle Orlando, Belgium
OP 4.1 – 10.45 – 10.57: COVID-19 associated coagulopathy in acute ischemic stroke patients treated with intravenous thrombolysis, Zsuzsa Bagoly, Hungary
OP 4.2 – 10.57 – 11.09: Joint effect of multiple prothrombotic genotypes and mean platelet volume on the risk of incident venous thromboembolism, Lisa Jakobsen, Norway
OP 4.3 – 11.09 – 11.21: Shear-induced platelet GPIbα shedding under extracorporeal membrane oxygenation promotes platelet clearance independently from von Willebrand factor-GPIbα interaction, Annabelle Dupont, France
OP 4.4 – 11.21 – 11.33: Effects of dietary palmitate on blood lipid profile and calcification of aorta and aortic valve, Nathalie Donis, Belgium
OP 4.5 – 11.33 – 11.45: Lower excess mortality in an anticoagulated population during the first wave of the COVID-19 pandemic in the Netherlands, Qingui Chen, The Netherlands
11.45
12.15
Meet the Expert
Location: Minneplein
- Factor XIII determination: why, when, and how, László Muszbek, Hungary
- Haemophilia and inhibitors, Samantha Gouw, The Netherlands
- Monitoring treatments with unfractionated heparin, Pierre Toulon, France
- New treatment options of haemophilia: challenges and opportunities, Cédric Hermans, Belgium
- Vitamin K and vessel wall, Leon Schurgers, The Netherlands
12.15
13.00
Lunch
13.00
14.00
Oral Communications
Chairs: John-Bjarne Hansen, Norway and Sofia Melo, Belgium
OP 5.1 – 13.00 – 13.12: A novel quali-quantitative defect of VWF, Tom van de Berg, The Netherlands
OP 5.2 – 13.12 – 13.24: Anti-cysteine/spacer autoantibodies that open the conformation of ADAMTS13 are a common feature of the autoimmune response in immune-mediated thrombotic thrombocytopenic purpura, Laure De Waele, Belgium
OP 5.3 – 13.24 – 13.36: GPVI is a binding partner for pro-coagulant factor VIII on platelets, Rohini Sekar, France
OP 5.4 – 13.36 – 13.48: Highly reactive juvenile platelets express higher levels of GPVI in a size-related manner, Alicia Veninga, The Netherlands
OP 5.5 – 13.48 – 14.00: SARS-CoV2 associated venous thromboembolism – a one-year follow-up, Alberto Maino, Italy
14.00
14.15
Short Break
14.15
15.15
Oral Communications
Chairs: Cédric Duval, United Kingdom and Thomas Vanassche, Belgium
OP 6.1 – 14.15 – 14.27: Prosthetic valve bioactive surface coating to reduce the prevalence of thrombosis, Cécile Oury, Belgium
OP 6.2 – 14.27 – 14.39: Venous Thromboembolism after Incident Colorectal Cancer in the Netherlands: Incidence, Predictors, and Prognosis, Rayna Anijs, The Netherlands
OP 6.3 – 14.39 – 14.51: Identification of two new ligands of the platelet CLEC-2 receptor, Luis A. Moran, United Kingdom
OP 6.4 – 14.51 – 15.03: Elevated plasma levels of the complement activating enzyme MASP-2 are associated with risk of future incident venous thromboembolism, Christabel Esi Damoah, Norway
OP 6.5 – 15.03 – 15.15: Role of Matrix Gla Protein in vascular calcification: hard chemistry for soft vessels, Stijn Agten, The Netherlands
15.15
15.45
Coffee Break and Poster Viewing
15.45
16.30
Keynote Lecture
Chair: Tilman Hackeng, The Netherlands
Venous thrombosis: From population studies to biological understanding, John-Bjarne Hansen, Norway
16.30
16.45
ECTH Closing